You are reading the report for 2026-08-26. The figures are as they stood that day and are not revised. See the current report →
Daily Special Report
Published Aug 27
Where the analysts disagree
The widest disagreement runs from ZYME's +100% to INTU's -12%, with opposite signs at the two ends. ZYME has the biggest gap between target and price of the 4 here, while INTU has the third-largest; NCNO's +11% is the smallest and SYRE's +13% the second-largest. Those figures compare the most recent target with the price when it was set, so the disagreement is about published targets rather than a shared current forecast.
INTU is the only company here at 0 up / 2 down, and its targets span $290 – $415, the biggest disclosed band of the 3 here. Its -12% gap between target and price is the only one of its kind here, while that gap is the third-largest of the 4 here.
targets $290-$415 · Barclays, Goldman Sachs, KeyBanc
For NCNO, targets run from $20 – $25, the smallest disclosed band of the 3 here. Its +11% gap between target and price is the smallest among the 4 here and the only one at +11%.
targets $20-$25 · Barclays, Morgan Stanley, Needham
A $121 – $123 band brackets SYRE, the second-largest disclosed band of the 3 here. Its +13% gap between target and price is the second-largest among the 4 here and the only one at +13%.
targets $121-$123 · BTIG, Wedbush
Unlike the other companies, ZYME has a disclosed band of —, the only one here. Its +100% gap between target and price is the biggest of the 4 here and the only one at +100%.
H.C. Wainwright
Grade changes and price targets published in the latest analyst feed. “Target vs price” compares the most recent target with the price at the time it was set. Analyst opinion is not a recommendation.